Analysis and Perspectives

Aug 23, 2024

Several pharmaceutical companies are developing a gene therapy that will positively impact the Duchenne Muscular Dystrophy Treatment Market

Aug 20, 2024

As per DelveInsight, the DMD market is expected to generate over $8,000 million in revenue in the 7MM

Jul 25, 2024

BMS has established a comprehensive treatment strategy, with CELMODs replacing REVLIMID in earlier lines of multiple myeloma treatment.

May 29, 2024

Artificial blood vessels represent a critical frontier in medical research, offering significant promise for treating cardiovascular diseases and enhancing surgical outcomes. Future directions in this field are focused on developing materials that can closely mimic the natural properties of human blood vessels.

May 27, 2024

Potential therapies are being investigated for retinal vein occlusion treatment. Even though it is too soon to comment on the promising candidate to enter the market, it is safe to assume that the future of the retinal vein occlusion treatment market is promising.

May 22, 2024

The future directions for the surgical camera market are promising, with a focus on enhancing image quality, reducing costs, and improving ease of use. Innovations such as 3D imaging, robotic integration, and artificial intelligence are expected to revolutionize the field, making surgeries more precise and less invasive.

Dec 11, 2023

FDA granted accelerated approval to Lilly’s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.

Dec 01, 2023

FDA recently approved Amgen’s Wezlana for various inflammatory conditions, marking the first biosimilar approval referencing the J&J Stelara.

Nov 29, 2023

Cryotherapy, a therapeutic technique utilizing extreme cold temperatures, has witnessed a significant evolution catalyzed by technological advancements, propelling its prominence in the healthcare industry. The integration of cutting-edge technology has revolutionized cryotherapy, enabling precise temperature contr...

Nov 27, 2023

The FDA has granted label extensions for two of the most vital global cancer drugs—Merck’s Keytruda and Pfizer and Astellas’ Xtandi.